Movement Alert|DexCom Intraday Rise 5.42% in Regular Trading, Q3 Beat and Higher Revenue Guidance Continued to Support Sentiment

Market Focus11-04

On November 4, DexCom rose 5.42% in Regular Trading, trading at $87.18/share, with turnover of $51.00 million.

The move followed continued digestion of the company’s late-October quarterly report, which showed third-quarter results above expectations and a higher full-year revenue outlook, alongside a subsequent price-target increase from Barclays.

DexCom reported adjusted EPS of $0.73 on revenue of $1.344 billion for the September quarter, above consensus estimates of $0.67 and $1.327 billion. The company lifted its full-year revenue guidance to $5.20 billion-$5.25 billion from $5.18 billion-$5.25 billion. Additional follow-up commentary indicated US share gains, near-record global new patient additions, progress toward converting nearly 50% of the US installed base to the 15-day G7 sensor by year-end, and a planned Canada launch in November, reinforcing expectations for stronger growth visibility beyond the current year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment